195 related articles for article (PubMed ID: 16783968)
21. Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer.
Lee HY; Chun KH; Liu B; Wiehle SA; Cristiano RJ; Hong WK; Cohen P; Kurie JM
Cancer Res; 2002 Jun; 62(12):3530-7. PubMed ID: 12068000
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
[TBL] [Abstract][Full Text] [Related]
23. Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy.
Ray P; Quantin X; Grenìer J; Pujol JL
Cancer Detect Prev; 1998; 22(4):293-304. PubMed ID: 9674872
[TBL] [Abstract][Full Text] [Related]
24. Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients.
Papadakis GZ; Mavroudis D; Georgoulias V; Souglakos J; Alegakis AK; Samonis G; Bagci U; Makrigiannakis A; Zoras O
Growth Horm IGF Res; 2017 Apr; 33():28-34. PubMed ID: 28258988
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of serum vascular endothelial growth factor and Angiopoietin-2 in patients with lung cancer.
Akın Kabalak P; Çiledağ A; Demir N; Çelik G; Yüksel C; Köycü G; Gökmen Öztuna D; Taner A; Kaya A; Kutlay H; Numanoğlu N; Savaş İ
Tuberk Toraks; 2015 Jun; 63(2):71-7. PubMed ID: 26167963
[TBL] [Abstract][Full Text] [Related]
26. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K; O'Byrne K; Cai RZ
Br J Cancer; 1994 Nov; 70(5):886-92. PubMed ID: 7947094
[TBL] [Abstract][Full Text] [Related]
27. Insulin-like growth factors stimulate the release of insulin-like growth factor-binding protein-3 (IGFBP-3) and degradation of IGFBP-4 in nonsmall cell lung cancer cell lines.
Noll K; Wegmann BR; Havemann K; Jaques G
J Clin Endocrinol Metab; 1996 Jul; 81(7):2653-62. PubMed ID: 8675593
[TBL] [Abstract][Full Text] [Related]
28. Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer.
Fürstenberger G; Senn E; Morant R; Bolliger B; Senn HJ
Breast; 2006 Feb; 15(1):64-8. PubMed ID: 15998587
[TBL] [Abstract][Full Text] [Related]
29. The value of serum Bcl-2 levels in advanced lung cancer patients.
Tas F; Duranyildiz D; Oguz H; Camlica H; Oral EN; Yasasever V; Topuz E
Med Oncol; 2005; 22(2):139-43. PubMed ID: 15965276
[TBL] [Abstract][Full Text] [Related]
30. Serum IGF-1 and IGFBP-3 levels as clinical markers for patients with lung cancer.
Tas F; Bilgin E; Tastekin D; Erturk K; Duranyildiz D
Biomed Rep; 2016 May; 4(5):609-614. PubMed ID: 27123256
[TBL] [Abstract][Full Text] [Related]
31. Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development.
Kim WY; Kim MJ; Moon H; Yuan P; Kim JS; Woo JK; Zhang G; Suh YA; Feng L; Behrens C; Van Pelt CS; Kang H; Lee JJ; Hong WK; Wistuba II; Lee HY
Endocrinology; 2011 Jun; 152(6):2164-73. PubMed ID: 21447628
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in patients with breast cancer.
Tas F; Karabulut S; Bilgin E; Tastekin D; Duranyildiz D
Tumour Biol; 2014 Sep; 35(9):9303-9. PubMed ID: 24943688
[TBL] [Abstract][Full Text] [Related]
33. Ifosfamide-based chemotherapy for previously treated lung cancer patients.
Chen YM; Liu JM; Wu MF; Wu HW; Lin WC; Tsai CM; Perng RP; Whang-Peng J
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):389-96. PubMed ID: 9699391
[TBL] [Abstract][Full Text] [Related]
34. Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 following chemotherapy for advanced breast cancer.
Holdaway IM; Mason BH; Lethaby AE; Singh V; Harvey VJ; Thompson PI; Evans BD
ANZ J Surg; 2003 Nov; 73(11):905-8. PubMed ID: 14616567
[TBL] [Abstract][Full Text] [Related]
35. Selective suppression of cytokine secretion in patients with small-cell lung cancer.
Fischer JR; Schindel M; Stein N; Lahm H; Gallati H; Krammer PH; Drings P
Ann Oncol; 1995 Nov; 6(9):921-6. PubMed ID: 8624296
[TBL] [Abstract][Full Text] [Related]
36. Molecular cloning of IGFBP-5 from SCLC cell lines and expression of IGFBP-4, IGFBP-5 and IGFBP-6 in lung cancer cell lines and primary tumours.
Wegmann BR; Schöneberger HJ; Kiefer PE; Jaques G; Brandscheid D; Havemann K
Eur J Cancer; 1993; 29A(11):1578-84. PubMed ID: 7692907
[TBL] [Abstract][Full Text] [Related]
37. [Association of insulin, insulin-like growth factor and insulin-like growth factor binding proteins with the risk of colorectal cancer].
Jiang B; Liu DB; Zhang X; DU LL; Han CZ
Zhonghua Wei Chang Wai Ke Za Zhi; 2009 May; 12(3):264-8. PubMed ID: 19434535
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer.
Chang YS; Kong G; Sun S; Liu D; El-Naggar AK; Khuri FR; Hong WK; Lee HY
Clin Cancer Res; 2002 Dec; 8(12):3796-802. PubMed ID: 12473592
[TBL] [Abstract][Full Text] [Related]
39. Association of serum retinol and carotenoids with insulin-like growth factors and insulin-like growth factor binding protein-3 among control subjects of a nested case-control study in the Japan Collaborative Cohort Study.
Suzuki K; Ito Y; Hashimoto S; Kawado M; Inoue T; Ando M; Watanabe Y; Inaba Y; Tajima K; Nakachi K; Tamakoshi A;
Asian Pac J Cancer Prev; 2009 Dec; 10 Suppl():29-35. PubMed ID: 20553078
[TBL] [Abstract][Full Text] [Related]
40. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer.
Tas F; Duranyildiz D; Argon A; Oğuz H; Camlica H; Yasasever V; Topuz E
Med Oncol; 2005; 22(4):353-8. PubMed ID: 16260852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
